NCT01039974View on ClinicalTrials.gov

GSK962040 Drug-drug Interaction Study With Ketoconazole

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 18, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Gastroparesis
Interventions
DRUG

GSK962040

"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"

DRUG

Ketoconazole

400 mg

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY